Bristol-Myers Squibb Announces Changes in Senior Management Team

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) today announced a series of related changes within its Senior Management Team.

Giovanni Caforio has been promoted to president, U.S. Pharmaceuticals. Caforio was most recently senior vice president, Oncology and Immunology Global Commercialization. In his new role, Caforio will report to Lamberto Andreotti, chief executive officer, and has been named a member of the Company’s Senior Management Team.

In addition, Charles Bancroft and Béatrice Cazala have been appointed Executive Vice Presidents of Bristol-Myers Squibb. Bancroft will add to his role of Chief Financial Officer operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim. Cazala will add responsibility for global policy to her role leading Global Commercialization, Europe and Emerging Markets. Both will continue to report to Andreotti and serve on the Company’s Senior Management Team.

Anthony C. Hooper, senior vice president, Commercial Operations, and president, U.S., Japan and Intercontinental, has decided to leave the company.

“A focus on developing talent at all levels is a key element of our Bristol-Myers Squibb culture,” Andreotti said. “I am excited to expand the roles of Giovanni, Charlie and Béatrice, and look forward to working with these three senior leaders and the rest of my management team to continue to successfully execute our BioPharma strategy.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Laura Hortas, 609-252-4587
[email protected]
or
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.